PDCD1 and Carcinoma, Lewis Lung: A preclinical study has indicated that a combination of gemcitabine (9) and anti-PD-1 therapy modulated the tumor immune microenvironment, including tumor infiltration, in a Lewis lung carcinoma (LLC) mouse model.